文献速递前列腺增生与排尿功能障碍

维贝格龙治疗接受药物治疗的良性前列腺增生男性持续性膀胱过度活动症症状的疗效与安全性:3期随机对照COURAGE试验结果

Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.
PubMed 文献 · J Urol · 2024-05-06

COURAGE试验将1105例≥45岁、接受α受体阻滞剂(联用或不联用5α还原酶抑制剂)治疗的良性前列腺增生合并膀胱过度活动症症状的男性随机分配至维贝格龙组或安慰剂组治疗24周。第12周时,维贝格龙较安慰剂显著减少每日排尿次数和尿急发作,并显著改善夜尿、急迫性尿失禁、IPSS储存评分和每次排尿量。不良事件发生率两组相似,维贝格龙安全且耐受良好。

要点

  • 维贝格龙较安慰剂显著减少每日排尿次数(最小二乘均值差-0.74次,P<.0001)。
  • 维贝格龙较安慰剂显著减少每日尿急发作(最小二乘均值差-0.95次,P<.0001)。
  • 不良事件发生率维贝格龙组45.0%与安慰剂组39.0%相似。

核心结论

  • 在该试验中,维贝格龙达到所有主要和次要终点,在合并膀胱过度活动症症状且接受药物治疗的良性前列腺增生男性中安全且耐受良好。

研究设计与样本

  • 3期随机对照试验,纳入≥45岁伴有膀胱过度活动症症状和良性前列腺增生、接受α受体阻滞剂联用或不联用5α还原酶抑制剂治疗的男性,按1:1随机分配至维贝格龙组或安慰剂组治疗24周。
  • 共随机分配1105例参与者,965例(87.3%)完成试验。

主要发现

  • 第12周时,维贝格龙组较安慰剂组显著减少每日排尿次数(最小二乘均值差[95%CI] -0.74[-1.02, -0.46];P<.0001)。
  • 第12周时,维贝格龙组较安慰剂组显著减少每日尿急发作(最小二乘均值差[95%CI] -0.95[-1.37, -0.54];P<.0001)。
  • 第12周时,维贝格龙组较安慰剂组显著改善夜尿发作(最小二乘均值差[95%CI] -0.22[-0.36, -0.09];P=.002)、急迫性尿失禁发作(-0.80[-1.33, -0.27];P=.003)、国际前列腺症状评分-储存评分(-0.9[-1.2, -0.6];P<.0001)和每次排尿量(15.07 mL[9.13-21.02];P<.0001)。
  • 不良事件发生率维贝格龙组为45.0%、安慰剂组为39.0%;发生率≥2%的不良事件包括高血压(9.0% vs 8.3%)、COVID-19(4.0% vs 3.1%)、尿路感染(2.5% vs 2.2%)和血尿(2.0% vs 2.5%)。

关键数值与推荐

  • 共同主要终点为第12周时平均每日排尿次数和尿急发作较基线的变化。
  • 次要终点为第12周时平均每晚夜尿次数、每日急迫性尿失禁发作、国际前列腺症状评分-储存评分和每次排尿量较基线的变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The efficacy and safety of vibegron, a β3-adrenergic receptor agonist, was assessed among men with symptoms of overactive bladder (OAB) receiving pharmacologic treatment for benign prostatic hyperplasia (BPH) in a phase 3 randomized controlled trial. MATERIALS AND METHODS: Men ≥ 45 years with OAB symptoms and BPH, treated with α-blocker with/without 5α-reductase inhibitors, were randomized 1:1 to vibegron or placebo for 24 weeks. Coprimary end points were change from baseline at week 12 in mean daily micturitions and urgency episodes. Secondary end points were change from baseline at week 12 in mean nightly nocturia and daily urge urinary incontinence episodes, International Prostate Symptom Score‒storage score, and volume voided per micturition. Safety was evaluated via adverse events (AEs). RESULTS: Of 1105 participants randomized, 965 (87.3%) completed the trial. At week 12, vibegron was associated with significant reductions vs placebo in daily micturitions (least squares mean difference [95% CI], -0.74 [-1.02, -0.46]; P < .0001) and urgency episodes (-0.95 [-1.37, -0.54]; P < .0001). Vibegron was also associated with significant improvements vs placebo at week 12 in nocturia episodes (least squares mean difference, -0.22 [-0.36, -0.09]; P = .002), urge urinary incontinence episodes (-0.80 [-1.33, -0.27]; P = .003), International Prostate Symptom Score‒storage scores (-0.9 [-1.2, -0.6]; P < .0001), and volume voided (15.07 mL [9.13-21.02]; P < .0001). AE rates were similar in vibegron (45.0%) and placebo (39.0%) arms; AEs occurring in ≥ 2% of participants were hypertension (9.0% vs 8.3%), COVID-19 (4.0% vs 3.1%), UTI (2.5% vs 2.2%), and hematuria (2.0% vs 2.5%). CONCLUSIONS: In this trial, vibegron met all primary and secondary end points and was safe and well tolerated in men with OAB symptoms and pharmacologically treated BPH.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Staskin D, Owens-Grillo J, Thomas E, et al. Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. J Urol. 2024. PMID: 38708869. doi:10.1097/JU.0000000000003999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。